NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Matinas BioPharma Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.62 -0.11 (-6.36 %) (As of 12/11/2019 04:00 PM ET) Add Compare Today's Range$1.50Now: $1.62▼$1.7150-Day Range$0.59MA: $0.68▼$0.7552-Week Range$0.50Now: $1.62▼$2.18Volume148,589 shsAverage Volume1.05 million shsMarket Capitalization$263.64 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Read More… Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:MTNB Previous Symbol CUSIPN/A CIKN/A Webhttp://www.matinasbiopharma.com/ Phone+1-908-4431860Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees15 Outstanding Shares162,740,000Market Cap$263.64 million Next Earnings Date4/7/2020 (Estimated) OptionableNot Optionable Receive MTNB News and Ratings via Email Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. AMEX:MTNB Rates by TradingView Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions What is Matinas BioPharma's stock symbol? Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB." How were Matinas BioPharma's earnings last quarter? Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.03). View Matinas BioPharma's Earnings History. When is Matinas BioPharma's next earnings date? Matinas BioPharma is scheduled to release their next quarterly earnings announcement on Tuesday, April 7th 2020. View Earnings Estimates for Matinas BioPharma. What price target have analysts set for MTNB? 4 equities research analysts have issued 1-year price objectives for Matinas BioPharma's shares. Their forecasts range from $3.00 to $5.00. On average, they expect Matinas BioPharma's stock price to reach $4.19 in the next twelve months. This suggests a possible upside of 158.5% from the stock's current price. View Analyst Price Targets for Matinas BioPharma. What is the consensus analysts' recommendation for Matinas BioPharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Matinas BioPharma. What are Wall Street analysts saying about Matinas BioPharma stock? Here are some recent quotes from research analysts about Matinas BioPharma stock: 1. HC Wainwright analysts commented, "Our price target of $4/share is based on an equally weighted composite of: (a) $2.47/share, as a 35x multiple of taxed and diluted 2033 EPS of $0.67 discounted back to 2019 at 18%; and (b) an NPV discounted cash flow between 2019-2033 of $4.81/share, with a discount rate of 12% and growth rate of 2%. These assumptions are in-line with the expected PE multiple and discount rates of an early development-stage biopharmaceutical company." (8/14/2019) 2. According to Zacks Investment Research, "Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia. " (7/17/2019) 3. Maxim Group analysts commented, "Matinas reported 1Q19 with a net loss of ($4.3M) and cash of $39.4M. This included a $32.4M financing completed in March, which should provide funding into 2021." (5/16/2019) Has Matinas BioPharma been receiving favorable news coverage? Media stories about MTNB stock have been trending somewhat negative recently, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Matinas BioPharma earned a coverage optimism score of -1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Matinas BioPharma. Are investors shorting Matinas BioPharma? Matinas BioPharma saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 5,530,000 shares, an increase of 5.1% from the October 31st total of 5,260,000 shares. Based on an average trading volume of 520,300 shares, the days-to-cover ratio is currently 10.6 days. Currently, 4.0% of the shares of the stock are short sold. View Matinas BioPharma's Current Options Chain. Who are some of Matinas BioPharma's key competitors? Some companies that are related to Matinas BioPharma include Concordia International (CXR), Polynovo (PNV), Mesoblast (MSB), Immutep (IMM), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Oxford BioMedica (OXB), Starpharma (SPL), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Biotest (BIO), Bellus Health (BLU), Neptune Wellness Solutions (NEPT), Pfenex (PFNX) and Pfenex (PFNX). What other stocks do shareholders of Matinas BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Vistagen Therapeutics (VTGN), Highpower International (HPJ), Synergy Pharmaceuticals (SGYP), Advaxis (ADXS), Marinus Pharmaceuticals (MRNS), Novavax (NVAX), Sorrento Therapeutics (SRNE) and Aphria (APHA). Who are Matinas BioPharma's key executives? Matinas BioPharma's management team includes the folowing people: Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 45)Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 72)Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 49)Dr. Theresa Matkovits, Chief Devel. Officer (Age 52)Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain Who are Matinas BioPharma's major shareholders? Matinas BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.24%). Company insiders that own Matinas BioPharma stock include Adam K Stern, Herbert J Conrad, Jerome D Jabbour, Keith A Kucinski and Patrick G Lepore. View Institutional Ownership Trends for Matinas BioPharma. Which major investors are buying Matinas BioPharma stock? MTNB stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, Herbert J Conrad, Jerome D Jabbour, Keith A Kucinski and Patrick G Lepore. View Insider Buying and Selling for Matinas BioPharma. How do I buy shares of Matinas BioPharma? Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Matinas BioPharma's stock price today? One share of MTNB stock can currently be purchased for approximately $1.62. How big of a company is Matinas BioPharma? Matinas BioPharma has a market capitalization of $263.64 million. Matinas BioPharma employs 15 workers across the globe.View Additional Information About Matinas BioPharma. What is Matinas BioPharma's official website? The official website for Matinas BioPharma is http://www.matinasbiopharma.com/. How can I contact Matinas BioPharma? Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860. MarketBeat Community Rating for Matinas BioPharma (NYSEAMERICAN MTNB)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 308 (Vote Outperform)Underperform Votes: 263 (Vote Underperform)Total Votes: 571MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/11/2019 by MarketBeat.com StaffFeatured Article: How to interpret a stock’s beta number
